Metastatic Breast Cancer

The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.

Innovative dosing strategies are warranted to improve the well-being of individuals with metastatic breast cancer, according to a patient advocate-led study published in JCO Oncology Practice.

The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.

Elizabeth A. Comen, MD, has been appointed associate professor in the department of medicine at NYU Langone Health’s Perlmutter Cancer Center.

Editor’s note: This is the third in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting that focused on the human side of oncology.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

Paolo Tarantino, MD, speaks with Healio about future research directions in metastatic breast cancer.

Paolo Tarantino, MD, highlights modifiable risk factors for metastatic breast cancer.